Daily MailWanted: New Developer for Stem Cell Tx in Refractory AnginaMedPage TodayNEW ORLEANS — The stem cells that have shown promise for refractory angina maintained their efficacy in a meta-analysis, as researchers once again made their case for a … Continue reading
FOX31 Denver |
Take Control of Your Pain with Stem Cell Institute of America
FOX31 Denver If you wake up every morning in pain, it’s time to take control of your health. There’s a new solution that requires no surgery and no downtime. And this revolutionary breakthrough medicine is now available to all of us, helping to diminish pain in … |
|
Where Bayer-Monsanto’s $66 billion merger stands now
St. Louis Business Journal … by Monsanto’s licensing agreement with gene-editing technology such as Harvard and MIT’s CRISPR-Cas9 and CRISPR–Cpf1. Monsanto Chief Technology Officer Robb Fraley told Reuters in September, before the announcement of the merger with Bayer, … |
UC Berkeley |
Sniffing out stem cell fates in the nose
UC Berkeley University of California, Berkeley, neuroscientists have now combined new techniques for sequencing the RNA in single cells with detailed statistical analysis to more easily track individual stem cells in the nose, uncovering clues that someday could … Scientists unveil the UK’s largest resource of human stem cells from healthy donorsScience Daily Ilkley businessman takes aim at future medicineIlkley Gazette This Week in NatureGenomeWeb |
UC Berkeley |
Scientists unveil the UK’s largest resource of human stem cells from healthy donors
Science Daily The Human Induced Pluripotent Stem Cell Initiative (HipSci) project used standardised methods to generate iPSCs on a large scale to study the differences between healthy people. Reference sets of stem cells were generated from skin biopsies donated by … Ilkley businessman takes aim at future medicineIlkley Gazette New Resource for Banked iPSCsThe Scientist This Week in NatureGenomeWeb |
Xconomy |
Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer
Xconomy The FDA approval for (NYSE: MRK) pembrozlizumab (Keytruda) to treat metastatic nonsquamous non-small cell lung cancer widens the use of the immunotherapy. Last year, the FDA approved it for lung cancer patients whose tumors produce a high amount … US FDA approves Merck immunotherapy/chemo combo for lung cancerReuters Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy ApprovalTheStreet.com Why Merck’s Keytruda Just Became a Lung Cancer Game ChangerFortune Channel NewsAsia –Business Wire –Merck Newsroom all 60 news articles » |